학술논문
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Document Type
Artikel
Author
Source
The Lancet. Oncology. 20(6):781-794
Subject
Language
English
English
English
ISSN
1474-5488